Register for free
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

62.52 +6.14 (+10.89%)
Streaming Delayed Price Updated: 3:35 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023
 
Via Benzinga
Expert Ratings for MoonLake
 
Via Benzinga
The 7 Most Promising Momentum Stocks to Own Now
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility. 
Via InvestorPlace
10 Analysts Have This to Say About MoonLake
 
Via Benzinga
Analyst Expectations for MoonLake's Future
 
Via Benzinga
Where MoonLake Stands With Analysts
 
Via Benzinga
Why MoonLake Immunotherapeutics Stock Skyrocketed This Week
Positive mid-stage results fueled a spike in the biotech's shares this week. 
Via The Motley Fool
Why Shares of MoonLake Immunotherapeutics Skyrocketed Monday
The company reported positive phase 2 clinical trial results. 
Via The Motley Fool
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
10 Short Squeeze Stocks To Watch: Baosheng Media, Toro Corp, Getty Images And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
Price Target For MoonLake Doubled: Analyst Says Lead Program Has 'Best-In-Class Profile'
HC Wainwright has increased the price target for MoonLake Immunotherapeutics (NASDAQ: MLTX) from $37 to $75  
Via Benzinga
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
Benzinga 
Via Benzinga
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022
MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for... 
Via Benzinga
10 Short Squeeze Stocks To Watch: Asset Entities, Lightning eMotors, Bullfrog AI, Carvana And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
$40M Bet On MoonLake Immunotherapeutics? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
10 Short Squeeze Stocks To Watch: A Leader That Moved Up 392 Positions, Intuitive Machines, Toro And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
MarketBeat Week in Review – 6/26 - 6/30
Markets headed into a holiday week cheering a lower-than-expected key inflation reading, but investors should expect volatility in a short trading week. 
Via MarketBeat
Topics Economy
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review
Major indexes rebounded strongly and many stocks flashed buy signals. 
Via Investor's Business Daily
MoonLake Immunotherapeutics Makes a Moonshot on Trials
Clinical-stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive clinical trial results. 
Via MarketBeat
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today
The heavily bullish sentiment on the company only grew on the second trading day of the week. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
MoonLake Immunotherapeutics, Applied Digital And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
BioMedNewsBreaks – MoonLake Immunotherapeutics’ (NASDAQ: MLTX) Shares See Significant Increase Based on Success of Phase 2 Trial
Via Investor Brand Network
Dow Surges Over 50 Points; Avalo Therapeutics Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining more than 50 points on Monday. The Dow traded up 0.18% to 33,788.05 while the NASDAQ fell 0.61% to 13,410.63. The S&P 500,... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular... 
Via Benzinga
Crude Oil Rises; Carnival Shares Drop After Q2 Results
U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 80 points on Monday. The Dow traded down 0.02% to 33,719.54 while the NASDAQ fell 0.53% to 13,420.67. The S&P 500, also... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS